Thu, Dec 25, 2014, 9:07 AM EST - U.S. Markets closed for Christmas


% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • erniewerner erniewerner Jan 18, 2013 11:06 AM Flag

    New Article

    Here is another article with a substantive Cabo mention. Appropriately it scales Cabo in after Abi, MDV, and Alpharadin. It is a good indicator of the expectation of the clinical community, which is a few steps in advance of the financial community. Dr. Raghavan is an outspoken and influential ODAC member so his interest in Cabo is a plus.

    Prostate Cancer: What did we learn from the 2012 Annual Scientific Meeting of ASCO?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • From the article:
      "Novel Agents
      Another avenue of progress has been the identification of other molecular pathways in prostate tumorigenesis that have led to the discovery of novel therapeutic targets. MET is a receptor tyrosine kinase associated with oncogenic signaling that is expressed in prostate cancer and bone metastasis and is negatively regulated by androgen signaling.[28,29] Inhibition of MET activity has proven effective in murine xenograft prostate cancer models.[30] Cabozantinib (XL-184) is a novel multi–tyrosine-kinase inhibitor with strong activity against MET and vascular endothelial growth factor (VEGF receptor) 2.[31] A randomized phase II study of cabozantinib in patients with mCRPC initially reported at ASCO last year was prematurely unblinded based on significant clinical activity.[32] A total of 86% of patients with lesions evaluable on bone scan demonstrated complete or partial resolution of skeletal lesions. In a study of an expanded nonrandomized cohort of 93 patients previously treated with docetaxel, reported this year,[33] 60% of patients demonstrated a partial response on bone scan, and 46% of patients had reduced narcotic requirements following treatment with cabozantinib. In 59 patients with ≥ 5 circulating tumor cells (CTCs) prior to therapy, 39% converted to

      Sentiment: Strong Buy

1.29-0.01(-0.77%)Dec 24 1:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Yahoo! Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST
Amira Nature Foods Ltd.
NYSEWed, Dec 24, 2014 1:04 PM EST